Anthropic 公布 Claude 自主设计 de novo 蛋白质结合体的实验结果：在 1320 个可测设计中 354 个结合目标，命中率 26.8%，15 个靶点中 14 个找到结合体。
Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.
推荐理由：论文给出 Claude 自主完成蛋白质设计全流程的可复现流程和实测命中率，便于评估智能体在科研实验中的实际边界。
